Clinical Trial

Trial Protocol ID USOR 22136_HLX10-020-SCLC302

Trial Description

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Tejaswi R Sastry, MD

Disease Types

Sponsor

  • Shanghai Henlius Biotech Co., Ltd.

ClinicalTrials.gov NCT ID

  • NCT05353257